TrumpRx, a initiative backed by former President Trump, has come under scrutiny following a recent analysis revealing that it covers significantly fewer drugs than initially promised. While the program was touted as a supermarket for cheaper medications, critics claim it has instead delivered a boutique service that falls short of expectations. Despite announcing a bold 59% cut in US prescription drug prices as part of a new pharmaceutical policy, many are questioning the effectiveness of TrumpRx in providing substantial relief to consumers. AMAC Magazine has claimed the program delivers massive price relief, but the reality appears more complex, leading to disappointment among advocates and patients seeking affordable options.